Патогенез и терапия анемии препаратами рекомбинантного эритропоэтина у онкогематологических больных (обзор современной литературы)

В статье представлен обзор литературы по механизмам развития анемии у больных онкогематологическими заболеваниями. Приведена классификация хронической анемии и методы ее коррекции. Подробно описаны механизмы действия, показания и побочные эффекты препаратов рекомбинантного эритропоэтина (рЭПО). Приведены алгоритмы лечения хронической анемии у пациентов с опухолевыми заболеваниями системы крови с помощью препаратов рЭПО. Представлен анализ эффективности препаратов рЭПО, используемых для терапии анемии у больных различными видами онкологических заболеваний. Представлены рекомендации ASCO/ASH по применению препаратов рЭПО у различных категорий больных.

1. Steurer M., Wagner H., Gastel G. Prevalence and management of anaemia in haematologic cancer patients receiving cyclic nonplatinum chemotherapy: results of a prospective national chart survey. Wien Klin Wochenschr 2004;116(11−12):367−72.

2. Truong P.T., Parhar T., Hart J. et al. Population‑based analysis of the frequency of anemia and its management before and during chemotherapy in patients with malignant lymphoma. Am J Clin Oncol

3. ;33(5):465−8.

4. Leitch H.A., Vickars L.M. Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron? Hematology Am Soc Hematol Educ Program 2009:664−72.

5. Ludwig H. Anemia of hematologic malignancies: what are the treatment options? Semin Oncol 2002;29(3 Suppl. 8):45−54.

6. Tefferi A., Lasho T.L., Jimma T. et al. One thousand patients with primary myelofibrosis: the mayo clinic experience. Mayo Clin Proc 2012;87(1) :25−33.

7. Cortes J., O’Brien S., Quintas A. et al. Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase. Cancer 2004;100(11) :2396−402.

8. Quintás‑Cardama A., De Souza Santos F.P., Kantarjian H. et al. Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure. Cancer 2009;115(17):3935−43.

9. Santos F.P., Alvarado Y., Kantarjian H. et al. Long‑term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib. Cancer 2011;117(5):982−91.

10. Passamonti F., Rumi E., Arcaini L. et al. Blast phase of essential thrombocythemia: A single center study. Am J Hematol 2009; 84(10):641−4.

11. Романенко Н.А., Абдулкадыров К.М. Патогенетическая коррекция анемии эритропоэзстимулирующими препаратами у больных лимфопролиферативными заболеваниями. Онкогематол 2011; 3:39−49.

12. Поспелова Т.И., Лямкина А.С. Уровень цитокинов (интерлейкина‑1β, фактора некроза опухолей‑α, интерферона‑γ, интерлейкина‑6) у больных лимфопролиферативными заболеваниями с анемическим синдромом. Анемия при лимфомах: научное издание. НГМУ. Новосибирск,2008. С. 97−114.

13. Цветаева Н.В., Левина А.А., Мамукова Ю.И. Основы регуляции обмена железа. Клин нкогематол 2010;3(3):278−83.

14. Fleming R.E., Sly W.S. Ferroprotein mutation in autosomal dominant hemochromatosis: loss of unction, gain in understanding. J Clin Inv 2001; 108:521−2.

15. Elliot S., Sinclair A.M. The effect of erythropoietin on normal and neoplastic cells. Biologics: argets and Therapy 2012; 6:163−89.

16. Tsopra O.A., Ziros P.G., Lagadinou E.D. et al. Disease-related anemia in chronic lymphocytic leukemia is not due to intrinsic defects of erythroid precursors: a possible pathogenetic role for tumor necrosis factoralpha. Acta Haematol 2009;121(4):187−95.

17. Птушкин В.В. Анемия в онкологии: подходы к лечению. Клин онкол 2012; 14(1):58−63.

18. Романенко Н.А., Абдулкадыров К.М. Применение препаратов рекомбинантно- го эритропоэтина у больных лимфопролиферативными заболеваниями. Медицинская технология. СПб., 2011. 30 c.

19. Oster H.S, Hoffman M., Prutchi‑Sagiv S. et al. Erythropoietin in clinical practice: current use, effect on survival, and future directions. Isr Med Assoc J 2006;8(10):703−6.

20. Aapro M.S., Link H. September 2007 update on EORTC guidelines and anemia management with erythropoiesisstimulating agents. Oncologist 2008;13(Suppl. 3):33−6.

21. Bokemeyer C., Aapro M.S., Courdi A. et al. EORTC guidelines for the use of erythropoietic proteins in anemic patients with cancer: 2006 update. Eur J Cancer 2007;43:258−70.

22. Приказ Минздрава РФ № 363 от 25 ноября 2002 года «Об утверждении Инструкции по применению компонентов крови».

23. Hedenus M., Adriansson M., San Miguel J. et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double‑blind, placebocontrolled study. Brit J Haematol 2003; 122:394−403.

24. Rizzo J.D., Brouwers M., Hurley P. et al. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood 2010;116(20):4045−59.

25. Romanenko N., Slascheva I., Golovchenko R., Abdulkadyrov K. Study of effectiveness recombinant human erythropoietin and quality of life in lymphoproliferative disorders patients with anemia. Haematologica 2011; 96(Suppl. 2):748.

26. Aapro M.S., Jelkmann W., Constantinescu S.N., Leyland-Jones B. Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer. Brit J Cancer 2012; 106:1249−58.

27. Brines M.L., Ghezzi P., Keenan S. et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000; 97(19):10526−31.

28. Kaptanoglu E., Solaroglu I., Okutan O. et al. Erythropoietin exerts neuroprotection after acute spinal cord injury in rats: effect on lipid peroxidation and early ultrastructural findings. Neurosurg Rev 2004;27(2) :113−20.

29. Kumral A., Uysal N., Tugyan K. et al. Erythropoietin improves longterm spatial memory deficits and brain injury following neonatal hypoxia-ischemia in rats. Behav Brain Res 2004;153(1):77−86.

30. Hayashi T., Suzuki A., Shoji T. et al. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 2000;35(2):250−6.

31. Parsa C.J., Matsumoto A., Kim J. et al. novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 2003; 112(7):999−1007.

32. Wright G.L., Hanlon P., Amin K. et al. Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J 2004;18(9):1031−3.

33. Yang W.S., Chang J.W., Han N.J., ark S.K. Darbepoetin alfa suppresses tumor necrosis factor-α‑induced endothelin‑1 production through antioxidant action in human aortic endothelial cells: role of sialic acid residues. Free Radic Biol Med 2011; 50(10):1242−51.

34. Cazzola M., Beguin Y., Kloczko J. et al. Once‑weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropiepoietin production. Br J Haematol 2003;122(3):386−93.

35. Gabrilove J.L., Cleeland C.S., Livingston R.B. et al. Clinical evaluation of once‑weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19(11):2875−82.

36. Hoffmann M., Schwenger V. Erythropoiesis stimulating agents. Ther Umsch 2011;68(11):650−4.

37. Canon J., Vansteenkiste J., Bodoky G. et al. Randomized, double-blind, activecontrolled trial of every‑3‑week darbepoetin alfa for the treatment of chemotherapyinduced anemia. J Natl Cancer Inst 2006; 98(4):273−84.

38. Henry D.H. Guidelines and recommendations for the management of anemia in patients with lymphoid malignancies. Drugs 2007;67(2):175−94.

39. Van Belle S., Karanikiotis C., Labourey J.L. et al. Current practice of darbepoetin alfa in the management of haemoglobin levels in cancer patients undergoing chemotherapy — data from the CHOICE study. Curr Med Res Opin 2011;27(5):987−94.

40. Haioun C., Salar A., Pettengell R. et al. Anemia and erythropoiesis-stimulating agent administration in patients with non‑Hodgkin lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisolone with/without rituximab chemotherapy: results from an observational study. Leukemia & Lymphoma 2011;52:796−803.

41. Delarue R., Haioun C., Coiffier B. et al. Survival effect of darbepoetin alfa in patients with diffuse large B‑cell lymphoma (DLBCL) treated with immunochemotherapy: The LNH03‑6B study. J Clin Oncol 2011; 29(Suppl.; abstr. 9048).

42. Hedenus M., Birgegård G., Näsman P. et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 2007;21(4) :627−32.

43. Henke M., Laszig R., Rube C. et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003; 362:1255−60.

44. Hershman D.L., Buono D.L., Malin J. et al. Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer. J Natl Cancer Inst 2009;101(23):1633−41.

45. Wright J.R., Ung Y.C., Julian J.A. et al. Randomized, double-blind, placebocontrolled trial of erythropoietin in non‑small‑cell lung cancer with diseaserelated anemia. J Clin Oncol 2007; 25(9):1027−32.

46. Bennett C.L., Silver S.M., Djulbegovic B. et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299(8):914−24.

47. Bohlius J., Wilson J., Seidenfeld J. et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98(10):708−14.

48. Bohlius J., Schmidlin K., Brillant C. et al. Recombinant human erythropoiesisstimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009;373:1532−42.

49. Khorana A.A., Francis C.W., Blumberg N. et al. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med 2008;168(21):2377−81.

50. Dammacco F., Silvestris F., Castoldi G.L. et al. The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy. Int J Clin Lab Res 1998;28(2):127−34.

51. Dammacco F., Castoldi G., Rodjer S. Efficacy of epoetin alfa in treatment of anemia of multiple myeloma. Br J Haematol 2001;113(1): 172−9.

52. Mittelman M. The implications of anemia in multiple myeloma. Clin Lymph 2003;4(Suppl. 1):23−9.52. Katodritou E., Terpos E., Zervas K. et al. Hypochromic erythrocytes (%): a reliable marker for recognizing iron-restricted erythropoiesis and predicting response to erythropoietin in anemic patients with myeloma and lymphoma. Ann Hematol 2007;86(5) :369−76.

53. Romanenko N.A., Golovtshenko R.A., Kostroma I.I., Abdulkadyrov K.M. Study of efficacy recombinant human erythropoietin in multiple myeloma patients with anemia. Haematologica 2012;97(Suppl. 1):622. 54. Richardson P., Schlag R., Khuageva N. et al. Characterization of haematological parameters with bortezomib–melphalan– prednisone versus melphalan–prednisonein newly diagnosed myeloma, with

54. evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial. Br J Haematol 2011; 153(2):212−21.

55. Santini V. Clinical use of erythropoietic stimulating agents in myelodysplastic syndromes. Oncologist 2011;16(Suppl. 3): 35−42.

56. Villegas A., Arrizabalaga B., Fernández‑Lago C. et al. Darbepoetin alfa for anemia in patients with low or intermediate‑1 risk myelodysplastic syndromes and positive predictive factors of response. Curr Med Res Opin 2011; 27(5):951−60.

57. Park S., Kelaidi C., Sapena R. et al. Early introduction of ESA in low risk MDS patients may delay the need for RBC ransfusion: a retrospective analysis on 112 patients. Leuk Res 2010;34(11):1430−6.

58. Cervantes F., Alvarez‑Larrán A., Hernández‑Boluda J.C. et al. Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. Br J Haematol 2004;127(4):399−403.

59. Nagel S., Kellner O., Engel‑Riedel W. et al. Addition of darbepoetin alfa to dose‑dense chemotherapy: results from a randomized phase II trial in small‑cell lung cancer patients receiving carboplatin plus etoposide. Clin Lung Cancer 2011; 12(1):62−9.

60. Eisterer W., Hussl C., Erb H. et al. RETRA: evaluating the transfusion rate with darbepoetin alfa 500 μg every 3 weeks n anaemic cancer patients receiving chemotherapy. Curr Med Res Opin 2011;27(2):355−63.

61. Steensma D.P., Sloan J.A., Dakhil S.R. et al. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. J Clin Oncol 2011;29(1):97−105.

62. Ludwig H., Crawford J., Osterborg A. et al. Pooled analysis of individual patientleveldata from all randomized, double-blind, lacebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol 2009;27(17):2838−47.

63. Vansteenkiste J., Glaspy J., Henry D. et al. Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: Study-level and patient-level meta‑analyses. Lung Cancer 2012;76(3):478−85.

64. Bastit L., Vandebroek A., Altintas S. et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 2008;26(10):1611−8.

65. Katodritou E., Speletas M., Zervas K. et al. Evaluation of hypochromic erythrocytes in combination with sTfR‑F index for predicting response to r‑HuEPO in anemic patients with multiple myeloma. Lab Hematol 2006;12(1):47−54.